After a study reported that physicians who authored dermatology clinical guidelines didn't always fully disclose financial conflicts of interest, the American Academy of Dermatology urged the public to view the findings with caution.
The public should view with caution the recent findings that authors of dermatology clinical practice guidelines (CPGs) may be receiving industry payments that they don’t fully disclose, according to a statement from the American Academy of Dermatology (AAD).
JAMA Dermatology published a study last week that raised concerns over potential financial conflicts of interest among physicians who help create dermatology CPGs. AAD responded to the study, and its president, Henry W. Lim, MD, FAAD, said that dermatologists who author guidelines are the experts in their field, and as such they often engage with companies on the cutting edge of research.
“In evaluating potential conflicts of interest among guidelines authors, the AAD does not consider research activities to be conflicts, as these activities are vital in advancing clinical knowledge and fueling dermatologic innovation,” Lim explained.
The study, and AAD, both noted that it was not clear how, or if, these industry payments influenced the physicians involved in the development of dermatology guidelines, and the study only assessed if the payments were relevant if the company made products related to the guideline. However, those physician relationships could be unrelated.
In an editorial that accompanied the study, Kenneth A. Katz, MD, MSc, MSCE, of Kaiser Permanente, explained that the question of industry ties among authors of CPGs is important, because “CPGs influence decision making by physicians, patients, and insurers.”
However, Katz raises 3 questions:
“The AAD stands by the strength and accuracy of its clinical guidelines, as well as the regulations in place to minimize the influence of potential conflicts of interest on the guidelines process,” Lim said. “While we maintain the guidelines studied in this paper were created in compliance with those regulations, we take seriously this issue, and continue to evaluate and refine our guidelines process to address both real and perceived potential conflicts of interest.”
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
2 Commerce Drive
Cranbury, NJ 08512